YahooSeptember 1, 2026 at 3:00 PM NY2 days ago
Moderna Rises 6% Despite GSK Moving Rival mRNA Flu Vaccine to Phase III
GSK just handed Moderna's biggest rival program a late-stage green light, yet traders are sending MRNA stock sharply higher. The logic behind that reaction tells you something important about where the real value of mRNA technology sits right now.
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site — Yahoo
Companies in This Story
Related Stories
Sodexo : Monthly disclosure on share capital and voting rights August 31, 2026
Yahoo1 hour ago
ANF vs. TPR: Which Stock Is the Better Value Option?
Yahoo1 hour ago
Anthropic's IPO Push Just Got a $15 Billion Backstop
Yahoo1 hour ago
Why Is Circle Internet Group, Inc. (CRCL) Up 63.1% Since Last Earnings Report?
Yahoo1 hour ago
Radian (RDN) Up 1.5% Since Last Earnings Report: Can It Continue?
Yahoo1 hour ago